Class 435/328 - Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.)

Subclass of Class 435 - Chemistry: molecular biology and microbiology
Definition: Subject matter involving an animal cell which produces an
No. of patents: 278
Last issue date: 04/17/2012

«First «Previous1 2 3 4 5 6 7 Next»Last»

Number	Title	Issue Date
8158419	Transgenic non-human animals for producing chimeric antibodies The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity. ...	04/17/2012
7803618	Recombinant tumor specific antibody and use thereof The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a ...	09/28/2010
7575923	CD19xCD3 specific polypeptides and uses thereof Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain,...	08/18/2009
7442775	Humanized anti-CCR2 antibodies and methods of use therefor The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to...	10/28/2008
7435549	Method of identifying binding site domains that retain the capacity of binding to an epitope The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further r...	10/14/2008
7435585	Auto-stimulating cells and methods for making and using the same Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. T...	10/14/2008
RE40535	Anti-KC4 humanized monoclonal antibody and cells that express the antibody An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with ...	10/07/2008
7429486	Recombinant production of mixtures of antibodies The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recomb...	09/30/2008
7429652	Compositions and methods for generating chimeric heteromultimers The present invention provides a technique for specific assembly of monomeric polypeptides to form a heteromultimer. This technique is particularly useful for generating a genetically diverse repertoire of heteromultimers such as antigen-binding units. The invention...	09/30/2008
7429487	Fusion partner for production of monoclonal rabbit antibodies The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, ...	09/30/2008
7425446	Antibody composition-producing cell The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region o...	09/16/2008
7419807	protein, gene sequence and uses thereof A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeu...	09/02/2008
7410781	IL-4/IL-13 specific polypeptides and therapeutic uses thereof Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases. ...	08/12/2008
7405275	Antibodies which bind human CXCR3 Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, a...	07/29/2008
7402410	Humanized immunoglobulin reactive with α4β7 integrin The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light ch...	07/22/2008
7388088	High affinity human antibodies to tumor antigens This invention provides for novel human antibodies that specifically bind to c-erbB-2. The antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2. ...	06/17/2008
7381560	Expression and use of anti-CD20 antibodies Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and s...	06/03/2008
7371723	Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc...	05/13/2008
7361345	Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the...	04/22/2008
7354762	Method for producing CE7-specific redirected immune cells Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ...	04/08/2008
7351816	Nucleic acid encoding anti-IgE antibodies The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.	04/01/2008
7351583	Antibodies to G protein-coupled receptor A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted ...	04/01/2008
7342110	Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved ver...	03/11/2008
7332582	Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-...	02/19/2008
7320790	Humanized antibodies Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transf...	01/22/2008
7318923	Humanized anti-βantibodies Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transfor...	01/15/2008
7319139	TAG-72 specific C2 domain deleted antibodies Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same...	01/15/2008
7316812	Cells expressing anti-Fc receptor binding components Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of th...	01/08/2008
7294701	Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same An antibody fragment and methods of utilizing same are provided. The antibody fragment includes an antigen binding region capable of binding an extracellular portion of a P-glycoprotein thereby at least partially inhibiting drug efflux activity in multidrug resistan...	11/13/2007
7285635	Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio...	10/23/2007
7273925	Methods and products for regulating lectin complement pathway associated complement activation The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are ...	09/25/2007
7264965	Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means A complex including an HLA class I molecule and attaching means for selectively attaching the HLA class I molecule to a target is disclosed, and a method is provided for producing or enhancing an immunological response against a target cell, by attaching said comple...	09/04/2007
7265209	CE7-specific chimeric T cell receptor Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ...	09/04/2007
RE39760	Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fr...	08/07/2007
7253263	Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3 The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives. ...	08/07/2007
7250493	FC fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc var...	07/31/2007
7241879	Immunoassays for anti-HCV antibodies HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays. ...	07/10/2007
7227003	Anti-TNF antibody fragments Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, pe...	06/05/2007
7208313	Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype. ...	04/24/2007
RE39548	Interleukin-5 specific recombinant antibodies An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody. ...	04/03/2007

«First «Previous1 2 3 4 5 6 7 Next»Last»

PatentStorm

Did You Know...

PatentStorm News

Class 435/328 - Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.)